At a glance
ClinicalIndex Comparison Record- ✓Stage IV metastatic non-small cell lung cancer
- ✓Measurable disease of at least 1.5 cm at ≥2 non-irradiated sites (≥1.5 cm short-axis for lymph nodes) with ≥1 visceral organ metastasis outside the brain
- ✓Prior cytotoxic chemotherapy with subsequent distant metastatic disease relapse or progression while on chemotherapy
- ✓Planned to receive or actively receiving checkpoint inhibitor immune therapy (≤4 months duration if already on therapy)
- ✕Active autoimmune disease, primary immunodeficiency, HIV/AIDS, or hepatitis B or C
- ✕Oral corticosteroid dependency
- ✕Uncontrolled or untreated brain metastases or CNS disease
- ✕Uncontrolled intercurrent illness including active infection, symptomatic heart failure, unstable angina, or cardiac arrhythmia
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of Response-Adapted Hypofractionated Radiation Therapy to Potentiate the Systemic Immune Response to Checkpoint Inhibitors in Non-Small Cell Lung Cancer
In Brief
A clinical study evaluating Radiation and Immuno-Therapeutic Agent for Non Small Cell Lung Cancer Metastatic. Completed, enrolled 35 participants across 1 site.
Detailed Summary
This study includes the additional use of radiation therapy in combination immunotherapy in order to determine whether the radiation may improve the response of non-small cell lung cancer to immunotherapy and to monitor any side effects.
Study Details
Timeline
Interventions
Radiation therapy will be administered in 3 or 5 fractions over 3-10 days, at a recommended dose of 8-15 Gy per fraction for 3 total fractions (total dose 24-45 Gy) or 6-10 Gy per fraction for 5 total fractions (total dose 30-50 Gy)
Immune checkpoint inhibitors that are FDA approved for use in patients with metastatic NSCLC will be acceptable for use concurrently with radiotherapy in this trial. The choice of agents will be at the treating medical oncologist's discretion, and include: * Nivolumab 240mg or 3 mg/kg once every 2 weeks (14 day cycle) * Pembrolizumab 200mg or 2 mg/kg once every 3 weeks (21 day cycle) * Atezolizumab 1200 mg once every 3 weeks (21 day cycle) These agents should be continued per standard of care until either disease progression or unacceptable toxicity.